Cargando…

How to diagnose and manage hepatic encephalopathy: a consensus statement on roles and responsibilities beyond the liver specialist

INTRODUCTION: Hepatic encephalopathy is defined as brain dysfunction caused by liver insufficiency and/or portosystemic shunting. Symptoms include nonspecific cognitive impairment, personality changes and changes in consciousness. Overt (symptomatic) hepatic encephalopathy is a common complication o...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shawcross, Debbie L., Dunk, Arthur A., Jalan, Rajiv, Kircheis, Gerald, de Knegt, Robert J., Laleman, Wim, Ramage, John K., Wedemeyer, Heiner, Morgan, Ian E.J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams And Wilkins 2016
Materias:	Original Articles: Liver Failure
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4885589/ https://www.ncbi.nlm.nih.gov/pubmed/26600154 http://dx.doi.org/10.1097/MEG.0000000000000529

Ejemplares similares

The impact of rifaximin-α on the hospital resource use associated with the management of patients with hepatic encephalopathy: a retrospective observational study (IMPRESS)
por: Hudson, Mark, et al.
Publicado: (2017)

In vitro efficacy of pro‐ and anticoagulant strategies in compensated and acutely ill patients with cirrhosis
por: Lisman, Ton, et al.
Publicado: (2018)

Real-world evidence of long-term survival and healthcare resource use in patients with hepatic encephalopathy receiving rifaximin-α treatment: a retrospective observational extension study with long-term follow-up (IMPRESS II)
por: Aspinall, Richard J, et al.
Publicado: (2022)

The improvement in body composition including subcutaneous and visceral fat reduces ammonia and hepatic encephalopathy after transjugular intrahepatic portosystemic shunt
por: Gioia, Stefania, et al.
Publicado: (2021)

Ammonia mediates cortical hemichannel dysfunction in rodent models of chronic liver disease
por: Hadjihambi, Anna, et al.
Publicado: (2017)

Effect of rifaximin on infections, acute‐on‐chronic liver failure and mortality in alcoholic hepatitis: A pilot study (RIFA‐AH)
por: Jiménez, César, et al.
Publicado: (2022)

Randomized, double-blind, controlled study of glycerol phenylbutyrate in hepatic encephalopathy
por: Rockey, Don C, et al.
Publicado: (2014)

The organic solute transporters alpha and beta are induced by hypoxia in human hepatocytes
por: Schaffner, Carlos A, et al.
Publicado: (2015)

Influenza A(H1N1)pdm09 vaccine effectiveness and other characteristics associated with hospitalization in chronic liver disease patients
por: Ohfuji, Satoko, et al.
Publicado: (2014)

PNPLA3 I148M (rs738409) genetic variant and age at onset of at-risk alcohol consumption are independent risk factors for alcoholic cirrhosis
por: Burza, Maria Antonella, et al.
Publicado: (2014)

Endoglin in human liver disease and murine models of liver fibrosis—A protective factor against liver fibrosis
por: Alsamman, Muhammad, et al.
Publicado: (2017)

Treatment with non‐selective beta‐blockers affects the systemic inflammatory response to bacterial DNA in patients with cirrhosis
por: Gimenez, Paula, et al.
Publicado: (2018)

Bacterascites: A study of clinical features, microbiological findings, and clinical significance
por: Oey, Rosalie C., et al.
Publicado: (2018)

Outcomes after placement of a SX‐ELLA oesophageal stent for refractory variceal bleeding—A national multicentre study
por: Pfisterer, Nikolaus, et al.
Publicado: (2018)

Controlled attenuation parameter does not predict hepatic decompensation in patients with advanced chronic liver disease
por: Scheiner, Bernhard, et al.
Publicado: (2018)

Collagen type IV remodelling gender‐specifically predicts mortality in decompensated cirrhosis
por: Lehmann, Jennifer, et al.
Publicado: (2019)

Characterization of inflammatory response in hepatorenal syndrome: Relationship with kidney outcome and survival
por: Solé, Cristina, et al.
Publicado: (2019)

Erectile dysfunction in cirrhosis is impacted by liver dysfunction, portal hypertension, diabetes and arterial hypertension
por: Paternostro, Rafael, et al.
Publicado: (2018)

Deprescribing medications that may increase the risk of hepatic encephalopathy: A qualitative study of patients with cirrhosis and their doctors
por: Williams, Sydni, et al.
Publicado: (2021)

Genetic variants of innate immunity receptors are associated with mortality in cirrhotic patients with bacterial infection
por: Schaapman, Jelte J., et al.
Publicado: (2020)

Age Matching of Elderly Liver Grafts With Elderly Recipients Does Not Have a Synergistic Effect on Long-term Outcomes When Both Are Carefully Selected
por: Gilbo, Nicholas, et al.
Publicado: (2019)

An Unusual Presentation of Posterior Reversible Encephalopathy Syndrome Following Liver Transplantation
por: Rajakumar, Akila, et al.
Publicado: (2022)

Comparison of the ability of the PDD-ICG clearance test, CTP, MELD, and MELD-Na to predict short-term and medium-term mortality in patients with decompensated hepatitis B cirrhosis
por: Cheng, Xiang-Pu, et al.
Publicado: (2016)

No difference in mortality between terlipressin and somatostatin treatments in cirrhotic patients with esophageal variceal bleeding and renal functional impairment
por: Hung, Tsung-Hsing, et al.
Publicado: (2016)

Helicobacter pylori infection among patients with liver cirrhosis
por: Pogorzelska, Joanna, et al.
Publicado: (2017)

Non‐invasive detection of portal hypertension by enhanced liver fibrosis score in patients with different aetiologies of advanced chronic liver disease
por: Simbrunner, Benedikt, et al.
Publicado: (2020)

Prediction of liver fibrosis severity in alcoholic liver disease by human microfibrillar‐associated protein 4
por: Madsen, Bjørn S., et al.
Publicado: (2020)

Low prevalence and disease severity of COVID‐19 in post‐liver transplant recipients—A single centre experience
por: Verma, Anita, et al.
Publicado: (2020)

The value of different CT‐based methods for diagnosing low muscle mass and predicting mortality in patients with cirrhosis
por: Paternostro, Rafael, et al.
Publicado: (2019)

Prevalence of and risk factors for anaemia in patients with advanced chronic liver disease
por: Scheiner, Bernhard, et al.
Publicado: (2019)

Clinical characteristics and management of 1572 patients with pyogenic liver abscess: A 12‐year retrospective study
por: Yin, Dalong, et al.
Publicado: (2020)

Prognostic impact of sarcopenia in cirrhotic patients stratified by different severity of portal hypertension
por: Paternostro, Rafael, et al.
Publicado: (2020)

MRI‐defined sarcopenia predicts mortality in patients with chronic liver disease
por: Beer, Lucian, et al.
Publicado: (2020)

Safety of direct oral anticoagulants in patients with advanced liver disease
por: Semmler, Georg, et al.
Publicado: (2021)

Coagulopathy is not predictive of bleeding in patients with acute decompensation of cirrhosis and acute‐on‐chronic liver failure
por: Campello, Elena, et al.
Publicado: (2021)

Mycophenolate mofetil decreases humoral responses to three doses of SARS‐CoV‐2 vaccine in liver transplant recipients
por: Meunier, Lucy, et al.
Publicado: (2022)

Quality of life in liver transplant recipients during the Corona virus disease 19 pandemic: A multicentre study
por: Gitto, Stefano, et al.
Publicado: (2022)

Differential fuel utilization in liver transplant recipients and its relationship with non‐alcoholic fatty liver disease
por: Siddiqui, Mohammad S., et al.
Publicado: (2022)

Final safety and efficacy results from a 106 real‐world patients registry with an ascites‐mobilizing pump
por: Stirnimann, Guido, et al.
Publicado: (2022)

A novel score predicts mortality after transjugular intrahepatic portosystemic shunt: MOTS ‐ Modified TIPS Score
por: Fürschuß, Luisa, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_ti9bj676den7dp1b0kmfpo4muq